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Abstract
 Background—Optical coherence tomography (OCT) is a powerful imaging modality to 
visualize tissue structures, with axial image pixel resolution as high as 1.6 μm in tissue. However, 
OCT is intrinsically limited to providing structural information as the OCT contrast is produced by 
optically scattering tissues.
 Methods—Gold nanorods (GNRs) were injected into the anterior chamber (AC) and cornea of 
mice eyes which could create a significant OCT signal and hence could be used as a contrast agent 
for in vivo OCT imaging.
 Results—A dose of 30 nM of GNRs (13 nm in diameter and 45 nm in length) were injected to 
the AC of mice eyes and produced an OCT contrast nearly 50-fold higher than control mice 
injected with saline. Furthermore, the lowest detectable concentration of GNRs in living mice AC 
was experimentally estimated to be as low as 120 pM.
 Conclusions—The high sensitivity and low toxicity of GNRs brings great promise for OCT 
to uniquely become a high-resolution molecular imaging modality.
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 INTRODUCTION
Optical coherence tomography (OCT) is a noninvasive imaging modality that provides real-
time, depth-resolved cross-sectional images of tissue.1 As the intrinsic contrast of OCT is 
based on optical scattering, OCT images show primarily structural information, highlighting 
the boundaries between tissues and tissue layers. Despite not providing physiological or 
molecular information of tissues, the structural information displayed by OCT is of high 
value, particularly because it is gained at very high spatial resolution (as low as 1 μm) and a 
depth of penetration of several millimetres.2 This has made OCT a rapidly adopted imaging 
modality for visualizing pathologies in a wide range of applications ranging from cancer 
imaging, cardiology3 and dentistry.4 The most widespread use of OCT is in ophthalmology. 
The optics of the eye and the accessibility, namely a clear cornea, make OCT a good 
candidate for non-contact imaging of the eye.5 The technology has become a first-line 
imaging modality for visualizing various diseases of the eye including age-related macular 
degeneration6 and diabetic retinopathy,7 as well as various abnormalities in the eye’s 
anterior segment,8 including the cornea, the lens and the iris.
Despite the unique imaging properties provided by OCT, its primary limitation is the 
inability to provide information with respect to the physiology and/or the molecular 
processes within a tissue of interest. Hence, in order to allow OCT to reach its full potential 
in providing such information, exogenous contrast agents must be used. This molecular 
imaging approach has been tested before with numerous imaging modalities including 
magnetic resonance imaging (MRI), positron emission tomography, fluorescence imaging,9 
Raman spectroscopic imaging,10 photoacoustic imaging11 and others.12 Several contrast 
agents have been used for the various optical and non-optical imaging modalities, including 
both small molecules13 (less than ~3 nm), nanoparticles14 (1–100 nm) and macroscopic 
particles15 (larger than 100 nm). However, to date, limited number of contrast agents have 
been demonstrated for OCT. An OCT contrast agent should exhibit a high optical scattering 
coefficient, as this reduces the coherency of the probe light beam and increases the OCT 
contrast. However, this imposes the use of nanoparticles, as molecules below ~20 nm in size 
exhibit negligible optical scattering.16
The use of nanoparticles as contrast agents is well established for various imaging 
modalities including MRI,17 fluorescence imaging,18 photoacoustic imaging19,20 and other 
modalities.21 Such contrast agents may be directly administered intravenously for 
angiographic purposes, as done with other imaging modalities,22,23 or may be molecularly 
targeted to proteins of interest.10–12,24 To allow OCT reach its full potential, highly 
scattering and biocompatible contrast agents must be designed.
For optical applications, of particular interest are gold-based nanoparticles, as they display a 
strong plasmonic resonance for interaction with light.16 In particular, rod-shaped gold 
nanostructures exhibit a red-shifted plasmonic resonance, whose peak wavelength depends 
primarily on the aspect ratio of the rod. As the aspect ratio of the gold nanorod (GNR) 
increases, the resonance peak wavelengths increases from 530 nm up to 1000 nm or more.25 
This shift of the peak resonance towards near infrared (NIR) wavelengths allows for deeper 
tissue penetrance.26
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Although several OCT contrast agents has been previously proposed,27–29 none that we 
know of has been shown to demonstrate a detectable signal in living tissues. In this work, we 
leverage recent advancements in the synthesis of GNRs with peak resonance at the NIR and 
demonstrate their use as contrast agents for OCT.
 METHODS
 GNR preparation
GNRs with an absorbance peak at 780 nm and 850 nm were used in this study (Nanopartz, 
Loveland, CO, USA). To prevent the raw GNRs from aggregating, the particles were 
suspended in cetyltrimethylammonium bromide (CTAB) by the manufacturer, which is 
potentially toxic for in vivo use. To make the GNRs more biologically compatible, we 
removed the CTAB and coated the GNRs with polyethylene glycol to render water solubility 
and to minimize potential toxicity effects. We have used thiol-terminated polyethylene 
glycol (PEG) to displace the cytotoxic CTAB from the surface of the GNRs. The presence of 
PEG introduces in vivo stealth characteristics to the GNRs. PEG forms a water-like layer on 
the surface of the GNRs, making them less visible to CD45+ leukocytes and subsets (T cells, 
myeloid cells, macrophages, neutrophils). This is done by taking 50 mL of 1.5 nM raw 
GNRs suspended in CTAB and centrifuged three times (5000 r.p.m. for 5 min, followed by 
7000 r.p.m. for 20 min, followed by 9000 r.p.m. for 20 min). After each centrifugation step, 
the supernatant was removed and the GNRs were suspended in 4 mL of DI water. We then 
incubated the GNRs in 1 mL of 5.4 mM PEG (HS-PEG5000-COOH) and incubated the 
solution for 96 h. The CTAB on the GNRs was replaced by thiol groups present on the HS-
PEG5000-COOH polymer using a process known as ligand exchange. Ligand exchange 
allows for the removal and replacement of CTAB from the surface of the GNRs in a 
controlled manner, thus preventing particle aggregation and allowing the particles to retain 
their size, shape and plasmon resonant characteristics.30,31
 Optical and electron microscopy characterization of the GNR
The GNR optical absorbance spectrum and extinction coefficient were calculated using the 
DU-640 spectrophotometer (Beckman Coulter, Brea, CA, USA). The final concentration of 
the particles after centrifugation and washes was calculated.
The transmission electron microscopy (TEM) analysis of the GNRs was done using a CM10 
transmission electron microscope (Philips, Amsterdam, Netherlands) operating at 80 kV. 
Analysis of distribution of particle sizes was done through calculating the sizes of 35 
random GNRs in the TEM images using ImageJ National Institutes of Health (NIH).
 Phantom studies
Two different sizes of GNRs were tested to measure their back-scattering properties based 
on the intensity of OCT signal. GNRs corresponding to a peak absorbance wavelength of 
780 nm (length = 43 ± 4.22 nm; axial diameter = 12 ± 0.25 nm) and 850 nm (length = 49.31 
± 6.9 nm; axial diameter = 12.09 ± 1.63 nm) were serially diluted and placed in 96-well 
plates. Four readings were conducted for each concentration of GNR solution. OCT image 
of each well was separately recorded using the 1-inch telecentric lens with the following 
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parameters: 2-mm lateral scan size, 200 A-lines per OCT B-scan, 1 B-scan and 1000 frames 
per B-scan.
 Animal injection
All animal experiments were performed in compliance with the University of Miami 
Institutional Animal Care and Use Committee (IACUC) Guidelines. Wild-type C57BL/6 
mice, age 9–16 months and weighing 25–30 g, were utilized for the study. The mice eyes 
were dilated using a 2.5% phenylephrine hydrochloride ophthalmic solution 10 min prior to 
administration of anaesthesia. The mice were anaesthetized through a peritoneal injection of 
(100 μL/20 mg) solution containing ketamine (1.5 mg/0.1 mL) and xylazine (0.3 mg/0.1 
mL) in sterile PBS. Corneal and AC injections were carried out after the animal was under 
anaesthesia. We standardized an AC injection technique which involved initially puncturing 
the AC to drain out fluid, then a 33-gauge blunt needle was inserted into the same opening 
and 3–5 μL of GNR solution was injected. We standardized a corneal injection where a 
linear superficial incision was created at the limbus of the mouse cornea, a stromal tunnel 
was created from the limbus to the central corneal stroma, and 5–10 μL of solution was 
injected using a 33-gauge blunt needle. OCT imaging was performed immediately after the 
corneal and AC injections were performed with the animal still under anaesthesia. The 
animals were placed in a custom-built holder which provided precise and reproducible 
alignment of the animals for OCT imaging.
To evaluate the OCT signal produced by GNR in living tissues, we first standardized a 
GNR-850 AC injection technique where 3–5 μL of solution was injected into the mice AC. 
GNR-850 diluted using matrigel were injected at concentrations of 30 nM, 7.5 nM, 1.9 nM, 
0.5 nM, 120 pM and 29 pM to evaluate the potential of GNR-850 as OCT contrast agents in 
living subjects. Matrigel, which does not have any inherent scattering capability, was used to 
localize the GNR-850 in the AC and prevent losses of GNR-850 due to leaking. 
Additionally, a naïve group of mice corneas not receiving injections was included (N = 2 
mice). Upon injection, mice AC were scanned using Bioptigen SDOIS spectral domain OCT 
instrument (Bioptigen, Durham, NC).32 The power of the sample arm illuminating the tissue 
was set to 720 μW, which is well within the American National Standards Institute limits.33
We then tested the applicability of GNR-780 as an OCT contrast agent by injecting 5–10 μL 
of GNR-780 at a concentration of 50 nM into the stroma of a mouse cornea. A control group 
of mice received intrastromal injection of balanced salt solution (BSS) into their corneas 
using the same injection technique. Additionally, a naïve group of mice corneas not 
receiving injections was included (N = 3 mice).
Finally, we aimed to assess the minimal detectable concentration of GNR-780 in living mice 
corneas. Using the same corneal injection technique, we injected mice corneas (N = 4 mice 
for four concentrations) with 5 μL of GNRs at decreasing concentrations ranging from 50 
nM to 0.05 nM.
We then created a three-dimensional (3D) rendering of the OCT image, as well as a rotating 
video of the 3D rendering (Supporting Information Video S1) using the commercial 
software Amira 5.3 (Visage Imaging San Diego, CA, USA). The 3D rendering visualizes 
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well the various anatomical structures of the cornea and highlights the GNR contrast in the 
cornea.
 Ultrahigh temporal and spatial resolution spectral domain OCT system
Commercially available Spectral Domain Ophthalmic Imaging System (SDOIS) from 
Bioptigen, Inc. was used for imaging the anterior segment of the mouse eye, using a 860 nm 
centre wavelength super luminescent diode with a bandwidth of 95 nm.
 Displaying and thresholding of OCT images
The maximum value for the colour scale was normalized such that the average OCT signal 
in an area in the AC that was not injected with GNR was equal across all images. This slight 
adjustment was needed so as to normalize for changes in absolute OCT signal in AC 
positioned physically closer to the telecentric lens of the OCT camera. The new colour scale 
with adjusted maximum value was therefore called OCT contrast (as opposed to OCT 
signal). These adjustments in maximum scale level were relatively small and did not exceed 
±13% at most. Furthermore, the OCT images displayed in this work exhibited some intrinsic 
and homogeneous noise. Therefore, the minimum value of the colour scale for displaying 
the images was selected to be 1.5 times the average noise in the background of the image.
 Statistical analysis
Statistical analysis of difference between two groups had been done using the two-sided 
student’s t-test.
 RESULTS
GNRs possess strong optical absorbance and scattering properties when illuminated by an 
incident light.25 In this work we demonstrate, that the strong optical scattering produced by 
GNRs can be used to create an OCT signal stronger than the background signal of some 
tissues in the eye. We demonstrate the utility of GNRs as OCT contrast agents in living 
animals and show that they produce strong signal in the eyes of living mice. To determine 
the optimal peak wavelength of GNRs for enhanced OCT contrast generation, two different 
sizes of GNRs were evaluated using a phantom setup. OCT images obtained from GNRs 
corresponding to peak absorbance wavelengths of 780 nm (GNR-780) and 850 nm 
(GNR-850), respectively, are shown in (Fig. 1a,b). The OCT signal produced by GNR-850 
was consistently higher than the signal produced by GNR-780 (Fig. 1c). The lowest 
detectable concentration for GNR-850 and GNR-780 is 230 pM and 750 pM, respectively. 
This is likely due to the greater overlap of the GNR-850 absorbance spectrum and the light 
source used in the spectral domain OCT system (860 ± 48 nm). This overlap causes 
collective, in-phase oscillations of conductive electrons at the surface of the GNRs known as 
localized surface plasmon resonance (LSPR) effect. The LSPR effect results in maxima of 
light scattering and absorption at the surface of the GNRs.30 An important advantage of 
GNR-850 and GNR-780 is the fact that they minimally overlap with other major endogenous 
absorbers such as oxygenated and deoxygenated hemoglobin (Fig. 2a). Finally, we 
characterized the diameter and length of the GNR-850 and their distribution using TEM 
(Fig. 2b,c). The GNR-850 were 12.09 ± 1.63 nm in diameter and 49.31 + 6.9 nm in length 
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(average ± standard deviation [SD]). The GNR-780 were 12 ± 0.25 nm in diameter and 43 
± 4.22 nm in length (average ± SD).
GNR-850 (29 pM) injected into the AC did not produce distinct contrast as compared with 
the background/matrigel (0 pM) injected AC (P < 0.23, two-sided student’s t-test), 
concentrations of 120 pM and higher produced significantly different OCT contrast (Fig. 3a) 
(P < 0.05, for any one of the groups). We used a region-of-interest (ROI) analysis to 
compute the difference in OCT signal from the AC of naïve, matrigel-injected and 
GNR-850-injected mice. Figure 3b shows the log–log plot of GNR-850 concentration 
plotted versus the normalized OCT intensities converted to contrast OCT and calculated 
using ROI analysis.
In vivo high-resolution OCT images of the mice corneas revealed a high OCT contrast in the 
cornea injected with GNR-780 as compared with the control corneas (Fig. 4). Although BSS 
alone produced no OCT signal (data not shown), eyes injected with BSS showed minimal 
OCT signal, likely due to the injection itself, which may have altered and slightly moved 
tissues in the cornea. We used an ROI analysis to compute the difference in OCT signal from 
the cornea of naïve, BSS-injected and GNR-780-injected mice. We found that the OCT 
signal from corneas injected with nanoparticles was three times higher than OCT signal 
from BSS-injected mice corneas and 7.5 times higher than OCT signal from naïve mice 
corneas. A minimum threshold of 1.5 times the OCT noise was applied to the images for 
better clarity and visibility of features.
We next aimed to quantify the lowest detectable concentration of GNR-780 in a mouse 
cornea by injecting GNR-780 at varying concentrations to the mice corneas. Although the 
lowest concentration of 0.05 nM produced an indistinguishable OCT contrast compared with 
control mice, mice injected with 0.5 nM produced a clear OCT contrast, slightly higher than 
the control mice. Concentrations of 5 nM and higher produced an even greater OCT contrast 
(Fig. 5b). Some mice have experienced slight thickening of the cornea because of the 
volume (5 μL) of the injection. However, all corneas returned to normal thickness of ~130 
μm by 48 h post-injection (data not shown).
The 3D OCT images were then quantitatively analysed by manually drawing ROI 
encapsulating the injection area in the cornea and calculating the average signal within this 
3D ROI (Fig. 5c). The analysis has confirmed the qualitative observation that mice injected 
with 0.05 nM were indistinguishable from control mice (P < 0.23, two-sided student’s t-
test), and all other injections gave an OCT contrast that was significantly higher than control 
mice signal (P < 0.05 for any one of the groups). As 0.5 nM concentration of GNR produced 
a signal 33% higher than control mice injected with BSS alone, it was extrapolated that 
about 0.37 nM of GNR is the in vivo sensitivity limit (i.e. the concentration where the signal 
to tissue background ratio equals to 1). As the endogenous OCT signal produced by the 
cornea was over 500% higher than the OCT instrument noise floor (P < 0.01), the sensitivity 
is hence limited by the endogenous tissue background signal.
We have characterized and demonstrated the application of GNRs as high-sensitivity 
contrast agents for OCT in living animals. The sensitivity limit in living mice corneas was 
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estimated to be 120 pM, comparable with the sensitivity limit of in vivo fluorescence 
imaging using comparable size and wavelength fluorescent nanoparticles.34 However, the 
fact that OCT imaging of GNRs can maintain such high sensitivity is particularly powerful 
as the images produced are at ultrahigh spatial resolution (3 μm).
 DISCUSSION
OCT is currently one of the leading diagnostic tools in ophthalmology, as it allows for non-
invasive, ultrahigh spatial resolution structural imaging of tissue morphology. In addition to 
ophthalmology, OCT has found broad range of applications as an in vivo cellular imaging 
technique for cardiology,35 dermatology,36 neurology37 and oncology.38 However, OCT is 
still currently limited in visualizing physiological and molecular features, as the mechanism 
of contrast is purely the optical scattering of tissues.
The field of ophthalmology has seen the most rapid adoption of OCT as a diagnostic device. 
The optically clear gel inside the eyeball as well as the optics of the eye lens makes the eye 
amenable for easy investigation using non-contact optical techniques. Apart from OCT, 
currently available clinical ophthalmic imaging instruments are primarily light-based and 
include: fundus photography, scanning laser ophthalmoscopy,39 fluorescein angiography40 
and indocyanine green angiography.23 Ophthalmic ultrasound devices41 are also used in the 
case of poor optical visualization such as in the case of haemorrhages or ocular tumours. 
However, all these imaging devices are limited in their ability to provide mostly 
morphological information about the eye structure and limited functional information. 
Therefore, disease detection and treatment monitoring is intrinsically limited to late-stage 
anatomic and vascular abnormalities. Moreover, these techniques cannot visualize the 
underlying molecular and physiological causes of a disease. Emerging OCT-based imaging 
modalities, such as magnetomotive OCT,29 show promise in providing molecular 
information through the use of contrast agents; however, these modalities require the use of 
an external coil and a large radiofrequency amplifier, which complicates the system 
significantly.
In contrast, by conjugating the GNRs described here to targeting moieties such as 
antibodies42 or peptides,43 one will likely be able to target the GNRs to disease-associated 
molecular targets12 and visualize them with OCT. A great benefit of using gold-based 
nanoparticles is the potential for lower cytotoxicity because of the inert properties of 
gold.44,45 Finally, another unique advantage of GNRs is that their peak absorbance may be 
tuned from 600 nm up to and over 1000 nm by altering the particle’s aspect ratio.46 
Furthermore, although the route of administration selected here was a local injection to the 
eye, future avenues would explore systemic administration alternatives, which may prove 
useful for specific cases where fast clearance rates are needed or when the molecular target 
of interest is vascular. It is likely that the clearance path of the GNR from the cornea is 
through the vasculature and lymphatic system at the corneal limbus. However, further 
studies would have to address this question separately. Finally, although GNRs were used in 
the current work, other agents, including other types of metallic and non-metallic 
nanoparticles, may eventually be useful as well.
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In order to visualize the GNRs in an OCT image, the OCT signal (light scattering) from the 
GNRs must exceed the OCT signal from the surrounding tissue. As different parts of the eye 
exhibit different background OCT signals, the sensitivity limit will change accordingly. 
Additionally, in the future, changing the OCT excitation light source to cover different 
wavelengths may further improve the sensitivity, as different parts of the eye have different 
absorbance spectra.47
We believe OCT molecular imaging using GNRs bears great promise to fundamentally 
change the way ophthalmic diseases are diagnosed today. Although this work primarily 
explores application in ophthalmology, the underlying physical principles of contrast 
enhancement are extendible to other areas such as cardiology35 and cancer imaging.38 This 
work provides an additional benefit that we did not need to modify the OCT instrumentation 
(such as in case of magnetomotive48 or photothermal OCT49). We anticipate that this work 
may also open opportunities for targeted molecular imaging agents in other non-ophthalmic 
OCT applications.
 Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. 
Gold nanorod (GNR) optical coherence tomography (OCT) phantom studies. (a) OCT 
images recorded of wells containing GNRs dissolved in D.I. water corresponding to peak 
extinction wavelength of 780 nm at increasing concentrations from 0 to 48 nM. (b) OCT 
images recorded of wells containing GNRs dissolved in D.I. water corresponding to peak 
extinction wavelength of 850 nm at increasing concentrations from 0 to 30 nM. (c) Graph 
depicting OCT contrast generated by GNRs versus concentration of GNRs present in each 
corresponding well. GNRs with an extinction peak at 850 nm display higher OCT contrast 
as compared with 780 nm GNRs for each of the concentrations tested.
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Figure 2. 
In vitro characterization of the gold nanorods (GNRs). (a) The optical absorbance spectrum 
of GNR-780 (green curve) and GNR-850 (orange curve) peaked at 780 nm and 850 nm, 
respectively. These are preferable wavelengths as the optical absorbance of oxygenated (red 
curve) and deoxygenated hemoglobin (blue curve) are minimal at these wavelengths. (b) 
Transmission electron microscopy image of the 850 nm GNR (length = 49.31 ± 6.9 nm; 
axial diameter = 12.09 ± 1.63 nm). (c) Transmission electron microscopy image of the 780 
nm GNR (length = 43 ± 4.22 nm; axial diameter = 12 ± 0.25 nm).
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Figure 3. 
Quantifying gold nanorod (GNR) detection limit in the anterior chamber (AC) in vivo. (a) 
Mice ACs were injected with 3–5 μL of GNR-850 nanoparticles at decreasing 
concentrations from 30 nM to 0 nM (N = 12 total mice). Control mice ACs were injected 
with Matrigel. Although mice injected with 29 pM of GNR-850 solution displayed contrast 
similar to control mice, concentrations of 120 pM and above produced a distinct detectable 
OCT signal. (b) Quantification of the OCT contrast (measured as signal from area of 
injection divided by signal from an area distant from the injection) was observed to increase 
with the GNR concentration, with the lowest detectable concentration being 120 pM. Below 
this concentration, the OCT contrast was about equal to the OCT contrast recorded from the 
control mice (denoted as Background in black dashed line). The error bars represent 
standard deviation of the OCT signal.
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Figure 4. 
OCT detection of GNR-780 in living mice corneas. Mice corneas were injected with 10 μL 
of GNR-780 at 50 nM (lower mouse), and control mice corneas were injected with 10 μL of 
balanced saline solution (middle mouse) or not injected at all (upper mouse). OCT cross-
sectional images through the mice eyes (white dotted line) visualized the high contrast 
created by the GNR-780 in the cornea (lower white arrow) as compared with control mice.
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Figure 5. 
Quantifying GNR detection limit in mouse cornea. (a) Mice corneas were injected with 5 μL 
of GNR nanoparticles at decreasing concentrations from 50 nM to 0.05 nM (N = 4 total 
mice), and control mice corneas were injected with balanced saline solution (BSS). 
Although mice injected with 0.05 nM exhibited OCT contrast similar to control mice, 
concentrations of 0.5 nM and above produced a distinct detectable OCT signal. The OCT 
images represent a cross-sectional slide through the cornea (white dashed line). (b) 
Quantification of the OCT contrast (measured as signal from area of injection divided by 
corneal signal from an area distant from the injection) was observed to increase with the 
GNR concentration, with the lowest detectable concentration being 0.5 nM. Below this 
concentration, the OCT contrast was about equal to the OCT contrast recorded from the 
control mouse that was injected with BSS (denoted as Background in black dashed line). 
The error bars represent standard deviation of the OCT signal. (c) 3D rendering of OCT 
image. Although naïve mice show minimal signal in the corneal stroma (upper eye), mice 
injected with 10 μL of GNR at 50 nM show a bright and distinct OCT signal from the 
corneal stroma (lower eye). The corneal structures (corneal stroma, limbus and iris) exhibit 
very consistent OCT signal intensities across both the naïve and injected eyes. For 3D 
rotating videos, see Supporting Information videos.
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